Sector News

Sanofi appoints Muzammil Mansuri as executive VP, strategy & business development

February 5, 2016
Life sciences

Sanofi announced the appointment of Muzammil “Muz” Mansuri as a new member of the Executive Committee, effective February 22, 2016. Mansuri joins Sanofi from Gilead Sciences and will take the position of executive vice president, strategy & business development.

Mansuri will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund.

“Muz brings a wealth of experience as a senior executive within the global biopharmaceutical industry,” said Olivier Brandicourt, CEO, Sanofi. “Muz’s deep understanding of business development and strategy of global biopharmaceutical organisations will allow him to contribute significantly to the overall Group strategy and make him a valuable addition to Sanofi and the Executive Committee.”

A dual citizen of the US and United Kingdom, Mansuri has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility. From 2007 to 2010, Mansuri was chairman and CEO at CGI Pharmaceuticals. Mansuri’s most recently was senior vice president, research & development strategy and corporate development at Gilead Sciences.

Mansuri holds a bachelor of science degree in chemistry and a Ph.D in organic chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University.

Source: pharmabiz

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach